{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"9.5","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"CR was assessed according to the International Myeloma Working Group (IMWG) 2006 response criteria. CR was defined as negative immunofixation of serum and urine and disappearance of soft tissue plasmacytomas and \\<5% plasmacytomas in the bone marrow. The percentage of participants with CR as assessed by the investigator is presented.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle OR 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.","id":"OG000","title":"Cohort 2: Relapsed Refractory/Refractory (rR/R) Multiple Myeloma (MM)"}],"paramType":"NUMBER","populationDescription":"All participants in Cohort 2 with a baseline efficacy evaluation and at least 1 post-baseline efficacy evaluation.","reportingStatus":"POSTED","timeFrame":"Up to approximately 78.5 months","title":"Complete Response (CR) in Cohort 2: Relapsed Refractory/Refractory (rR/R) Multiple Myeloma (MM)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}